Description: Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Home Page: jaspertherapeutics.com
JSPR Technical Analysis
2200 Bridge Pkwy
Redwood City,
CA
94065
United States
Phone:
650 549 1400
Officers
| Name | Title |
|---|---|
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Chair of Scientific Advisory Board & Director |
| Mr. Jeetinder Singh Mahal M.B.A. | CFO, COO & Corp. Sec. |
| Dr. Kevin N. Heller M.D. | Exec. VP of R&D |
| Mr. Ronald A. Martell | Pres, CEO & Director |
| Dr. Susan Prohaska Ph.D. | Co-Founder and VP of Operations & Program Management |
| Dr. Carol Zoltowski | Sr. VP of Regulatory Affairs & Quality |
| Dr. Wendy Pang M.D., Ph.D. | Sr. VP of Research & Translational Medicine |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.0942 |
| Price-to-Book MRQ: | 0.5066 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-09-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 36 |